Back to Results
First PageMeta Content
Medicine / Clinical medicine / Health / Bristol-Myers Squibb / Hepatology / Infectious causes of cancer / RTT / Brivanib alaninate / Indoles / Hepatocellular carcinoma / Liver cancer / Hepatitis


Bristol-Myers Squibb and ZAI Lab Enter Licensing Agreement to Develop, Manufacture and Commercialize Brivanib in China SHANGHAI) – Bristol-Myers Squibb Company (NYSE: BMY) and ZAI Lab Limited (ZAI Lab), a le
Add to Reading List

Document Date: 2015-09-06 03:07:12


Open Document

File Size: 358,25 KB

Share Result on Facebook